NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10575905		
	Filing Date		2007-04-30		
	First Named Inventor	Hatto	nietal.		
	Art Unit		1644		
	Examiner Name	Ilia I.	Ouspenski		
	Attamen Dealest Number		14975 04041104		

U.S.PATENTS							Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Patentee or Applicant Relevan			s,Columns,Lines where vant Passages or Relevant es Appear		
	1										
If you wis	h to ad	id additional U.S. Pat	ent citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pat of cited Docu	Releva		Lines where		
	1										
If you wis	h to ad	d additional U.S. Pub	lished Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² j		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to ad	id additional Foreign I	Patent Do	cument	citation	information p	lease click the Add	button	Add		_
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			

1	TARDITI et al., "Selective high-performance liquid chromatographic purification of bispecific monocional antibodies," J. Chromatogr., 599.13-20 (1992)	
2	TEN KATE et al., "Effect of soelectric point on biodistribution and inflammation; imaging with indium-111-labelled igG," Eur. J. Nucl. Med., 17:305-309 (1990)	
3	TSURUSHITA et al., "Design of humanized antibodies: From anti-Tac to Zenapax," Methods, 36:69-83 (2005)	
4	WU et al., "Development of motavizumab, an ulta-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract," J. Mot. Biol., 368:652-665 (2007)	
5	YAMASAKI et al., "Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors," J. Pharmacol. Exp. Ther., 301.467-477 (2002)	
6	YANG et al., "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation," Protein Eng., 16:761-770 (2003)	
7	ZUCKIER et al., "Chimeric human-mouse tgC antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life," Cancer Res., 56:3905-08 (1998)	
8	International Search Report for App. Ser. No. PCT/JP2009/057309, mailed July 7, 2009, 8 pages	
9	EXAMINER MEERA NATARAJAN, USPTO Restriction Requirement in U.S. App. Ser. No. 12/295,039, dated October 12, 2010, 9 pages	
10	International Preliminary Report on Patentiability for App. Ser. No. PCTI/P2007/057036, dated October 21, 2008, 6 pages	
11	International Search Report for App. Ser. No. PCT/JP2007/057036, dated May 1, 2007, 2 pages	

12	European Search Report for App. Ser. No. 07 74 0494, dated September 3, 2009, 3 pages	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

18ee Kint Code of USPTO Petert Documents at Invest/ISPTO_GOLY or MPEP 901.04. I Enter office that issued the document, by the Involved (WIPO) Standard 51.3.) For Legareses patient counters, the included on the year of the register or interpretable to self-antimeted the patient counter. A for including the counter of the patient or interpretable is self-antimeted to patient counters. If Note that counters are considered to the patient of the patient or interpretable is a standard and the document under WIPO Standard 51.6 if possible. Supplicant is to place a check mark here if English languages translation is stated.